Mid Atlantic Bio Angels

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Hilltop Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for veterinary applications, particularly for horses and dogs. Established in 2018 and based in Norton, Massachusetts, the company specializes in room temperature placental allograft therapies designed to aid in the regeneration of damaged tissues and reduce inflammation. Hilltop Bio offers a range of products, including ophthalmic membrane patches for eye ulcers, orthopedic injectable treatments for tendon and ligament injuries, and surgical membrane patches that serve as anti-adhesion barriers. The company is committed to delivering safe and effective regenerative therapies that promote rapid healing, addressing key inflammatory diseases in companion and performance animals.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

New View Surgical, Inc. is a medical device company based in Boston, Massachusetts, that specializes in the development and commercialization of the VisionPort technology. This innovative system consolidates four essential surgical devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. The VisionPort system aims to enhance minimally invasive surgical procedures by providing surgeons with complete control over visualization and instrumentation. Founded in 2009, the company is led by a team of experienced professionals dedicated to addressing unmet needs in the medical field, offering potential clinical and economic advantages for operating rooms worldwide.

Seneca Therapeutics, Inc. is a biotechnology company based in Blue Bell, Pennsylvania, specializing in the development of oncolytic immunotherapeutics for cancer treatment. The company's primary product is the Seneca Valley Virus (SVV), an oncolytic virus designed to selectively replicate within and eliminate tumor cells. Seneca Therapeutics aims to advance SVV as a versatile therapeutic option, offering it in the form of cancer therapeutics, cancer vaccines, and vaccines for infectious diseases. Additionally, the company focuses on creating targeted biologics that can work in conjunction with immune checkpoint inhibitors and cancer vaccines, enhancing treatment efficacy and addressing immune tolerance in patients. Incorporated in 2018, Seneca Therapeutics is dedicated to providing innovative solutions for various types of cancer.

Astrocyte Pharmaceuticals Inc. is a drug development company focused on creating neuroprotection therapies for conditions such as traumatic brain injuries (TBI), concussions, acute ischemic stroke, and neurodegenerative disorders like Alzheimer's disease. Founded in 2014 and located in Cambridge, Massachusetts, the company is dedicated to demonstrating the neuroprotective benefits of selectively activating astrocytes. Its lead product, AST-004, is a novel small molecule designed for acute administration, aiming to protect and repair damaged neurons. Through its innovative approaches, Astrocyte Pharmaceuticals seeks to improve the recovery and well-being of patients suffering from brain injuries.

Sana Health, Inc. is a digital health company specializing in a bio-therapeutic device aimed at fostering relaxation to alleviate pain and tension. The company has developed a non-addictive mask and headphone system that employs audio-visual stimulation to enhance the balance between the brain's left and right hemispheres, facilitating a deep state of meditation. This innovative device uses coordinated pulses of light and sound to guide users into a restorative state, thereby improving mental well-being and addressing chronic pain and insomnia. In addition to the hardware, Sana Health offers a mobile application available on both the App Store and Google Play, allowing users to access its features conveniently. Founded in 2015 and headquartered in Lafayette, Colorado, with an additional office in Mill Valley, California, Sana Health is involved in pivotal studies concerning its technology's applications for conditions such as fibromyalgia and neuropathic pain, as well as trials focusing on anxiety and PTSD.

New View Surgical, Inc. is a medical device company based in Boston, Massachusetts, that specializes in the development and commercialization of the VisionPort technology. This innovative system consolidates four essential surgical devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. The VisionPort system aims to enhance minimally invasive surgical procedures by providing surgeons with complete control over visualization and instrumentation. Founded in 2009, the company is led by a team of experienced professionals dedicated to addressing unmet needs in the medical field, offering potential clinical and economic advantages for operating rooms worldwide.

Healionics Corporation, founded in 2007 and based in Seattle, Washington, specializes in the development and manufacturing of synthetic biomaterials and implantable medical devices aimed at improving healthcare for kidney failure patients. The company has created STARport HD, an implantable device that enables needle-free access to the bloodstream for hemodialysis, and STARgraft, a synthetic vascular graft designed to maintain long-term blood flow without frequent interventions. Healionics' innovations address critical challenges in dialysis treatment, particularly the unreliability of current vascular access methods, which can lead to costly complications. Their STAR biomaterial technology enhances the performance of medical implants by reducing infection and scar tissue formation. Healionics is preparing to initiate human studies for its products, with a focus on improving patient outcomes and reducing overall treatment costs in the dialysis sector.

Virion Therapeutics, LLC is a biotechnology company focused on developing immune-based treatments for virally associated cancers and chronic viral infections. Founded in 2018 and headquartered in Newark, Delaware, the company offers innovative vaccines, ChiVax and ChiVax-gD, which aim to induce potent and sustained T cell-mediated immune responses against transformed or infected cells. These chimeric vaccine candidates have successfully completed pre-clinical testing, paving the way for clinical trials targeting diseases with significant unmet medical needs, such as HPV-induced cancers and chronic Hepatitis B infections. Virion Therapeutics combines scientific expertise with management experience to advance its immunotherapy platforms, which may ultimately improve patient outcomes in the fight against these challenging health issues.

FEMSelect Inc. specializes in designing and developing surgical systems and devices for pelvic floor ligament fixation, focusing on women's health. The company is known for its innovative EnPlace system, a minimally invasive and mesh-free solution for treating pelvic organ prolapse (POP). This patented technology allows for precise guidance and deployment of an anchor unit that stabilizes the pelvic floor ligament through a vaginal approach, significantly enhancing patient recovery and comfort. The procedure typically takes about 30 minutes and does not require overnight hospital stays or result in visible scarring. Founded in 2012, FEMSelect operates from its headquarters in Newark, Delaware.

Elysium Therapeutics is a healthcare company established in 2013 and located in Danville, California. The company specializes in biotechnology and has developed innovative opioid pain relievers aimed at reducing the risks associated with oral misuse, abuse, and fatal overdose. Elysium Therapeutics' opioid medications are designed to automatically regulate opioid levels in the bloodstream, preventing them from exceeding safe limits. This approach not only minimizes the potential for addiction and adverse side effects but also enhances the ability of medical practitioners to manage pain effectively in patients requiring opioid-based treatments.

Opsidio is a biotechnology company based in Bryn Mawr, Pennsylvania, founded in 2012. The company specializes in developing monoclonal antibodies aimed at treating fibrotic and remodeling diseases, as well as allergic conditions. Opsidio's innovative antibodies specifically target a unique form of the Stem Cell Factor, which plays a crucial role in the cascade of profibrotic cytokines. This targeted approach enables healthcare providers to address various serious conditions, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, and severe asthma, ultimately improving treatment options for affected patients.

PainQx, Inc. is a diagnostic and software company that specializes in developing innovative healthcare solutions for both human and veterinary applications. Founded in 2015 and based in New York, the company has created the PainQx System, a platform that objectively measures pain by analyzing neural activity from a patient’s brain. Utilizing proprietary algorithms, the system processes EEG data to produce a scaled pain and neurological side effects biomarker that correlates directly with a patient's pain state. This technology serves as a clinical assessment tool for organizations that require accurate pain measurement in clinical trials, particularly where pain is a primary or secondary endpoint for evaluating the efficacy of drugs or medical devices. PainQx operates on a pay-per-use or subscription model, making its advanced diagnostic capabilities accessible to a broad range of healthcare providers.

New View Surgical, Inc. is a medical device company based in Boston, Massachusetts, that specializes in the development and commercialization of the VisionPort technology. This innovative system consolidates four essential surgical devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. The VisionPort system aims to enhance minimally invasive surgical procedures by providing surgeons with complete control over visualization and instrumentation. Founded in 2009, the company is led by a team of experienced professionals dedicated to addressing unmet needs in the medical field, offering potential clinical and economic advantages for operating rooms worldwide.

Genome Profiling, LLC is a bioinformatics company specializing in the discovery of novel epigenetic biomarkers to aid in the diagnosis, treatment, and prediction of chronic and life-threatening diseases. Established in 2012 and located in Wayne, Pennsylvania, the company offers GenPro Analytics, a software platform designed for scientists and medical professionals. This platform improves the sensitivity, specificity, and accuracy of disease prediction and monitoring while also being cost-effective. Genome Profiling is notable for its innovative approach, combining a proprietary pre-NGS gDNA preparation kit with advanced NGS data analytics algorithms. This integration allows a single NGS run to generate comprehensive data for both genomic variant analysis and epigenetic research, positioning the company at the forefront of the emerging epigenetic biomarker market.

Evrys Bio, LLC specializes in the development of innovative antiviral drugs that target sirtuins, proteins that play a vital role in enhancing the body's natural immunity against infections. The company offers a range of antiviral treatments for various conditions, including respiratory syncytial virus, herpes virus, polyomavirus infections, and viral encephalitis. Additionally, Evrys Bio develops therapies for liver infections caused by hepatitis C, hepatitis B, and human cytomegalovirus. Founded on research from Princeton University, the company aims to create first-in-class antivirals that are safe, effective against drug-resistant pathogens, and provide broad-spectrum treatment options. By focusing on the intrinsic immune responses of host cells, Evrys Bio seeks to transform the management of infectious diseases by addressing them holistically rather than targeting specific virus types. Established in 2012 and based in Doylestown, Pennsylvania, the company was previously known as FORGE Life Science, LLC before rebranding in May 2019.

Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing nucleic acid immunotherapy platforms for the treatment of cancer, allergies, and animal health. Founded in 2005 and based in Rockville, Maryland, with an additional office in South Korea, the company utilizes its UNiversal Intracellular Targeted Expression (UNITE) platform and the LAMP-Vax technology. The LAMP-Vax platform is designed to enhance immune system responses through the presentation of antigens via lysosomal-associated membrane proteins. This innovative approach aims to harness the body's natural biochemistry to promote immune responses, including antibody production and immunological memory, thereby transforming treatment options in the fields of allergy and cancer immunotherapy.

Cerus Endovascular Ltd specializes in designing and developing interventional neuroradiology devices aimed at the minimally invasive treatment of neurovascular diseases, with a primary focus on intracranial aneurysms. Founded in 2011 and headquartered in Oxford, United Kingdom, with an additional location in Fremont, California, the company has created the e-clipse device, an aneurysm occlusive tool. This device offers a novel alternative to existing treatment methods, including surgical clipping, metal coils, and liquid embolics. Cerus Endovascular's products cater to a variety of aneurysm morphologies and are particularly beneficial for treating hemorrhagic strokes, enabling interventional neuroradiologists to effectively address complex cases in a less invasive manner.